BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 20637357)

  • 1. Protein kinases: From targets to anti-cancer drugs.
    Cruzalegui F
    Ann Pharm Fr; 2010 Jul; 68(4):254-9. PubMed ID: 20637357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics.
    Kirkland LO; McInnes C
    Biochem Pharmacol; 2009 May; 77(10):1561-71. PubMed ID: 19167366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated technology platform protein kinases for drug development in oncology.
    Sachsenmaier C; Schächtele C
    Biotechniques; 2002 Oct; Suppl():101-6. PubMed ID: 12395934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and implementation of three mitogen-activated protein kinase (MAPK) signaling pathway imaging assays to provide MAPK module selectivity profiling for kinase inhibitors: MK2-EGFP translocation, c-Jun, and ERK activation.
    Nickischer D; Laethem C; Trask OJ; Williams RG; Kandasamy R; Johnston PA; Johnston PA
    Methods Enzymol; 2006; 414():389-418. PubMed ID: 17110204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting cancer with small-molecular-weight kinase inhibitors.
    Fabbro D; Cowan-Jacob SW; Möbitz H; Martiny-Baron G
    Methods Mol Biol; 2012; 795():1-34. PubMed ID: 21960212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SRC as a potential therapeutic target in solid tumor oncology.
    Gallick GE
    Clin Adv Hematol Oncol; 2004 Jul; 2(7):435-7. PubMed ID: 16163218
    [No Abstract]   [Full Text] [Related]  

  • 9. A functional approach to questions about life, death, and phosphorylation.
    Bernards R
    Cancer Cell; 2005 Jun; 7(6):503-4. PubMed ID: 15950899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Polyoxometalates. A new class of inorganic CK2 inhibitors].
    Prudent R; Hasenknopf B; Cochet C
    Med Sci (Paris); 2008 Dec; 24(12):1012-4. PubMed ID: 19116103
    [No Abstract]   [Full Text] [Related]  

  • 11. Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease.
    Force T; Kuida K; Namchuk M; Parang K; Kyriakis JM
    Circulation; 2004 Mar; 109(10):1196-205. PubMed ID: 15023894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promises and drawbacks of targeting cell cycle kinases in cancer.
    Pentimalli F; Giordano A
    Discov Med; 2009 Dec; 8(43):177-80. PubMed ID: 20040266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding.
    Bogoyevitch MA; Fairlie DP
    Drug Discov Today; 2007 Aug; 12(15-16):622-33. PubMed ID: 17706543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High affinity targets of protein kinase inhibitors have similar residues at the positions energetically important for binding.
    Sheinerman FB; Giraud E; Laoui A
    J Mol Biol; 2005 Oct; 352(5):1134-56. PubMed ID: 16139843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single cell network profiling (SCNP): mapping drug and target interactions.
    Covey TM; Putta S; Cesano A
    Assay Drug Dev Technol; 2010 Jun; 8(3):321-43. PubMed ID: 20158439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel therapeutic targets.
    Farley J; Birrer MJ
    Cancer Treat Res; 2009; 149():63-84. PubMed ID: 19763431
    [No Abstract]   [Full Text] [Related]  

  • 18. Targeted cancer therapy: promise and reality.
    Klein S; Levitzki A
    Adv Cancer Res; 2007; 97():295-319. PubMed ID: 17419951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting mTOR for cancer treatment.
    Rubio-Viqueira B; Hidalgo M
    Curr Opin Investig Drugs; 2006 Jun; 7(6):501-12. PubMed ID: 16784020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting cancer with kinase inhibitors.
    Gross S; Rahal R; Stransky N; Lengauer C; Hoeflich KP
    J Clin Invest; 2015 May; 125(5):1780-9. PubMed ID: 25932675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.